Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2020 Filed Jun 19, 2020 23:03 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 15,000 | $57.90 | $868,521.00 |
DisclosureSEC source: 0000874015-20-000072 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,935 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.59 to $58.36, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4 Read SEC document |
| June 10, 2020 Filed Jun 18, 2020 00:15 UTC |
HERMAN JOAN EDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000070 · edgar.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,665 Underlying: Common Stock · 3,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| June 10, 2020 Filed Jun 18, 2020 00:15 UTC |
HERMAN JOAN EDirector
|
Exercise / conversionCommon Stock | 3,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000070 · edgar.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:00 UTC Amendment |
Cadoret-Manier OnaizaChief Corp Dev and Cml Officer
|
GrantRestricted Stock Unit · Derivative | 22,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000068 · edgar.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 22,667 shares Expires not disclosed F1 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · kind: The original Form 4 filed on January 17, 2020 reported Restricted Stock Units granted to the reporting person on January 15, 2020, which has been revised by this amendment to reflect the actual grant date. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 23:05 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 1,000 | $47.00 | $47,000.00 |
DisclosureSEC source: 0000874015-20-000066 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 5,581 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 23:05 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 15,000 | $47.00 | $705,000.00 |
DisclosureSEC source: 0000874015-20-000066 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,935 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 22:17 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 1,000 | $45.00 | $45,000.00 |
DisclosureSEC source: 0000874015-20-000062 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,581 F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 22:17 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 5,000 | $46.00 | $230,000.00 |
DisclosureSEC source: 0000874015-20-000062 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 22:17 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 10,000 | $44.75 | $447,546.00 |
DisclosureSEC source: 0000874015-20-000062 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.50 to $45.07, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCOMMON STOCK | 4,349 | $45.00 | $195,705.00 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCOMMON STOCK | 5,651 | $45.00 | $254,295.00 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,894 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCOMMON STOCK | 5,421 | $44.50 | $241,234.50 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCOMMON STOCK | 4,969 | $44.50 | $221,120.50 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,966 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 4,349 | $45.00 | $195,705.00 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,935 F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 5,651 | $45.00 | $254,295.00 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,284 F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 5,421 | $44.50 | $241,234.50 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,935 F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 4,579 | $44.50 | $203,765.50 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,356 F1 · shares: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| February 29, 2020 Filed Mar 4, 2020 00:18 UTC |
Swayze EricSVP, Research
|
OtherCommon Stock | 378 | $43.16 | $16,315.61 |
DisclosureSEC source: 0000874015-20-000058 · edgar.xml · nonDerivative · entry 1 Swayze Eric · CIK 0001791058 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,301 F1 · kind: Reporting 378 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 378 shares may not be sold until August 30, 2020. Read SEC document |
| February 29, 2020 Filed Mar 4, 2020 00:16 UTC |
O'NEIL PATRICK R.SVP & General Counsel
|
OtherCommon Stock | 289 | $43.16 | $12,474.11 |
DisclosureSEC source: 0000874015-20-000056 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,009 F1 · kind: Reporting 289 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 289 shares may not be sold until August 30, 2020. Read SEC document |
| February 29, 2020 Filed Mar 4, 2020 00:14 UTC |
Monia Brett PDirector · Chief Executive Officer
|
OtherCommon Stock | 314 | $43.16 | $13,553.18 |
DisclosureSEC source: 0000874015-20-000054 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,957 F1 · kind: Reporting 314 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 314 shares may not be sold until August 30, 2020. Read SEC document |
| February 29, 2020 Filed Mar 4, 2020 00:12 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
OtherCommon Stock | 147 | $43.16 | $6,344.96 |
DisclosureSEC source: 0000874015-20-000052 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,374 F1 · kind: Reporting 147 shares acquired under the Ionis Pharmeceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 147 shares may not be sold until August 30, 2020. Read SEC document |
| February 29, 2020 Filed Mar 4, 2020 00:11 UTC |
Geary Richard SSVP, Development
|
OtherCommon Stock | 378 | $43.16 | $16,315.61 |
DisclosureSEC source: 0000874015-20-000050 · edgar.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,446 F1 · kind: Reporting 378 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 378 shares may not be sold until August 30, 2020. Read SEC document |
| February 29, 2020 Filed Mar 4, 2020 00:09 UTC |
BENNETT C FRANKChief Scientific Officer
|
OtherCommon Stock | 169 | $43.16 | $7,294.55 |
DisclosureSEC source: 0000874015-20-000048 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,364 F1 · kind: Reporting 169 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 169 shares may not be sold until August 30, 2020. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 22:40 UTC |
O'NEIL PATRICK R.SVP & General Counsel
|
SaleCommon Stock | 3,882 | $59.60 | $231,367.20 |
DisclosureSEC source: 0000874015-20-000045 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,720 F1 · kind: The sale of shares owned was made pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/7/2020. F1 · shares: The sale of shares owned was made pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/7/2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.55 to $59.65, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:15 UTC |
Cadoret-Manier OnaizaChief Corp Dev and Cml Officer
|
GrantRestricted Stock Units · Derivative | 22,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000026 · edgar.xml · derivative · entry 1 Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 22,667 shares Expires not disclosed F1 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:30 UTC |
Geary Richard SSVP, Development
|
Exercise / conversionRestricted Stock Units · Derivative | 13,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000031 · edgar.xml · derivative · entry 4 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,639 Underlying: Common Stock · 13,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:30 UTC |
Geary Richard SSVP, Development
|
GrantRetricted Stock Units · Derivative | 24,205 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000031 · edgar.xml · derivative · entry 3 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,205 Underlying: Common Stock · 24,205 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:30 UTC |
Geary Richard SSVP, Development
|
Tax withholdingCommon Stock | 4,654 | $62.06 | $288,827.24 |
DisclosureSEC source: 0000874015-20-000031 · edgar.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,068 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:30 UTC |
Geary Richard SSVP, Development
|
Exercise / conversionCommon Stock | 13,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000031 · edgar.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:47 UTC |
Swayze EricSVP, Research
|
Exercise / conversionRestricted Stock Units · Derivative | 6,522 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000041 · edgar.xml · derivative · entry 4 Swayze Eric · CIK 0001791058 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,653 Underlying: Common Stock · 6,522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:47 UTC |
Swayze EricSVP, Research
|
GrantRestricted Stock Units · Derivative | 12,235 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000041 · edgar.xml · derivative · entry 3 Swayze Eric · CIK 0001791058 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,235 Underlying: Common Stock · 12,235 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:47 UTC |
Swayze EricSVP, Research
|
Tax withholdingCommon Stock | 2,367 | $62.06 | $146,896.02 |
DisclosureSEC source: 0000874015-20-000041 · edgar.xml · nonDerivative · entry 2 Swayze Eric · CIK 0001791058 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,923 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:47 UTC |
Swayze EricSVP, Research
|
Exercise / conversionCommon Stock | 6,522 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000041 · edgar.xml · nonDerivative · entry 1 Swayze Eric · CIK 0001791058 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:42 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 15,136 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000039 · edgar.xml · derivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,409 Underlying: Common Stock · 15,136 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:42 UTC |
PARSHALL B LYNNEDirector
|
Tax withholdingCommon Stock | 3,905 | $62.06 | $242,344.30 |
DisclosureSEC source: 0000874015-20-000039 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,797 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:42 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionCommon Stock | 15,136 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000039 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 12,045 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · derivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,552 Underlying: Common Stock · 12,045 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
GrantRestricted Stock Units · Derivative | 24,205 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,205 Underlying: Common Stock · 24,205 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Tax withholdingCommon Stock | 4,277 | $62.06 | $265,430.62 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,602 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Exercise / conversionCommon Stock | 12,045 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:36 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 19,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000035 · edgar.xml · derivative · entry 5 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,087 Underlying: Common Stock · 19,921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:36 UTC |
Monia Brett PDirector · Chief Executive Officer
|
GrantPerformance Restricted Stock Units · Derivative | 17,009 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000035 · edgar.xml · derivative · entry 4 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,009 Underlying: Common Stock · 17,009 shares Expires not disclosed F6 · derivative.exercise_price: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated. F7 · derivative.exercise_price: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F6 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated. F6 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:36 UTC |
Monia Brett PDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 65,979 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000035 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,979 Underlying: Common Stock · 65,979 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:36 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 7,563 | $62.06 | $469,359.78 |
DisclosureSEC source: 0000874015-20-000035 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,643 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:36 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 19,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000035 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:33 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 12,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000033 · edgar.xml · derivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,550 Underlying: Common Stock · 12,044 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:33 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
GrantRestricted Stock Units · Derivative | 26,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000033 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 26,800 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:33 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Tax withholdingCommon Stock | 4,277 | $62.06 | $265,430.62 |
DisclosureSEC source: 0000874015-20-000033 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,227 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:33 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 12,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000033 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC |
CROOKE STANLEY TDirector · Executive Chairman of Board
|
Exercise / conversionRestricted Stock Units · Derivative | 3,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,627 Underlying: Common Stock · 3,317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.